ライフサイエンスコーパス: acute stroke

1 patients (medical patients and patients with acute stroke).

2 he prevalence of associated risk factors for acute stroke.

3 edes ascending blood flow) in the context of acute stroke.

4 hospital-acquired pneumonia in patients with acute stroke.

5 on (MA) constitutes a key tissue response in acute stroke.

6 ls may be sensitive to perfusion deficits in acute stroke.

7 lowing delayed intravenous administration in acute stroke.

8 f the evidence to guide BP management during acute stroke.

9 ood pressure (BP) and patient outcome during acute stroke.

10 tic information for patients presenting with acute stroke.

11 patients who were admitted with symptoms of acute stroke.

12 clinical decision-making in the treatment of acute stroke.

13 g children and young adults hospitalized for acute stroke.

14 decision-making in the clinical treatment of acute stroke.

15 or the purpose of lesion-behavior mapping in acute stroke.

16 ietin (EPO) is a potential new treatment for acute stroke.

17 possible novel mode of metabolic imaging in acute stroke.

18 for platelets, is elevated in patients with acute stroke.

19 th GCS in patients admitted to hospital with acute stroke.

20 ty of thyroid hormone levels in prognosis of acute stroke.

21 the extent of ischemic injury in an event of acute stroke.

22 herapies with and without adjuvants to treat acute stroke.

23 in the setting of recanalization therapy for acute stroke.

24 ompare CT and MRI for emergency diagnosis of acute stroke.

25 (56 of 217; 20-32%) for the diagnosis of any acute stroke.

26 to allow improved treatment of patients with acute stroke.

27 ferred for emergency assessment of suspected acute stroke.

28 ccurate diagnosis of patients with suspected acute stroke.

29 pulmonary embolism, sepsis, myocarditis, and acute stroke.

30 hibition is a promising treatment option for acute stroke.

31 dimensions of recovery and disability after acute stroke.

32 eas of epidemiology, therapy, and imaging of acute stroke.

33 stem, and represents a promising therapy for acute stroke.

34 as a risk factor for death in patients with acute stroke.

35 l utility for the treatment of patients with acute stroke.

36 -arginine should be avoided in patients with acute stroke.

37 on of cerebral hemodynamics in patients with acute stroke.

38 in the affected hemispheres of patients with acute stroke.

39 normal-attenuation regions in patients with acute stroke.

40 currently the only FDA-approved therapy for acute stroke.

41 vorable versus poor recovery from neglect in acute stroke.

42 ) to evaluate its measurement performance in acute stroke.

43 d specific features of favorable recovery in acute stroke.

44 ent of the DASH as an upper limb measure for acute stroke.

45 ee trials of aspirin versus control in major acute stroke.

46 glycemia aggravates ischemic brain damage in acute stroke.

47 utcome in patients with hyperglycemia during acute stroke.

48 to intravenous thrombolysis in patients with acute stroke.

49 g pneumonia in patients with dysphagia after acute stroke.

50 ional outcome and mortality in patients with acute stroke.

51 ively affects motor learning and severity of acute stroke.

52 nities to effectively intervene in and treat acute strokes.

53 plaques were identified in 20 patients with acute stroke (21 [27%] culprit, 12 [15%] probably culpri

54 ments from six other trials of alteplase for acute stroke (2775 patients).

55 ower-extremity peripheral artery disease and acute stroke (35% and 24%, respectively), whereas most v

56 Of 63 650 patients admitted with acute stroke, 55 838 (88%) had a dysphagia screen, and 2

57 tal-based cohort of patients presenting with acute stroke, acid-suppressive medication use was associ

58 Of 16 202 acute stroke admissions, 19.1% were transferred.

59 study cohort comprised 74,307 patients with acute stroke admitted to 199 hospitals.

60 Consecutive patients with acute stroke admitted to a stroke unit between April 200

61 Patients with acute stroke admitted to hospitals in Oxford, UK, were a

62 Infection is a major complication of acute stroke and causes increased mortality and morbidit

63 ent may contribute to preventing deaths from acute stroke and could be implemented even in settings w

64 ving the functional outcome in patients with acute stroke and hyperglycemia.

65 stigation of microvessel diameter changes in acute stroke and identifies its potential as an importan

66 Raised blood pressure is common after acute stroke and is associated with an adverse prognosis

67 course to advance thrombolytic treatment for acute stroke and promises to improve outcomes in acute s

68 tissue characterization in diseases such as acute stroke and tumor.

69 Sixteen patients with acute stroke and two with head trauma who had undergone

70 ere admitted to hospital within 1 week of an acute stroke and who were immobile were enrolled from 64

71 acute myocardial infarction, heart failure, acute stroke, and dialysis) were identified and meta-ana

72 tes: well, acute myocardial infarction (MI), acute stroke, and history of MI or stroke.

73 Although patients with acute stroke are routinely evaluated for potential treat

74 Therapeutic options for acute stroke are still limited.

75 Up to 50% of patients with acute stroke are taking antihypertensive drugs on hospit

76 very of thrombolytic agents in patients with acute stroke, are therapeutic modalities that are now wi

77 atients (mean age = 63.4 +/- 9.0 years) with acute strokes attributed to high-grade (>/=70%) intracra

78 ional, single-arm study of real-world MT for acute stroke because of anterior-circulation large-vesse

79 these hypotheses by evaluating patients with acute stroke before reorganization of structure-function

80 ss following mechanical thrombectomy (MT) in acute stroke but is undetermined whether the two scores

81 Patients without clinical evidence of acute stroke but with magnetic resonance imaging evidenc

82 gh blood pressure is a prognostic factor for acute stroke, but blood pressure variability might also

83 ve been implicated in the pathophysiology of acute stroke, but the role of mitochondrial DNA (mtDNA)

84 ifficult in some cases because patients with acute stroke can present with atypical or uncommon sympt

85 A centralized model for acute stroke care across an entire metropolitan city app

86 and magnitude of variation in the quality of acute stroke care across the entire week.

87 actors, and equity of access to high-quality acute stroke care and rehabilitation will probably reduc

88 tors and, thus, the likely effect of optimum acute stroke care and secondary prevention in reducing t

89 vention that can have an immediate impact on acute stroke care in a region.

90 ently being used to give alteplase and guide acute stroke care in eight rural community hospitals in

91 Studies examining the impact of organised acute stroke care interventions on survival in subgroups

92 f a range of evidence-based interventions of acute stroke care on one year survival post-stroke and d

93 osite measure of hospital-level adherence to acute stroke care performance metrics, stroke volume, an

94 etwork is an effective way to extend quality acute stroke care to remote hospitals and to improve pat

95 ratio (OR) for receiving five indicators of acute stroke care was 0.81 (95% CI 0.72 to 0.92).

96 2010 a new multiple hub-and-spoke model for acute stroke care was implemented across the whole of Lo

97 was obtained from other experts involved in acute stroke care.

98 ke, with the aim of ensuring access to rapid acute stroke care.

99 ed adjusted odds ratios for 13 indicators of acute stroke-care quality by fitting multilevel multivar

100 In the workup of acute stroke, carotid MPRAGE-positive signal was associa

101 All subjects had acute stroke causing unilateral arm weakness and had som

102 In patients with acute stroke, certain findings accurately increase or de

103 urtosis (MK) was sensitive to hyperacute and acute stroke changes, and exhibited different contrast t

104 lights a potential complementary role in the acute stroke clinical decision-making process.

105 h similarities and points of divergence with acute stroke clinical trial design.

106 spheres in 7 patients with diabetes after an acute stroke compared with 12 stroke patients without di

107 172 people with acute stroke completed the DASH.

108 roving the delivery of care to patients with acute stroke, cost-effectiveness, and logistical issues

109 ustrate the essential role of reperfusion in acute stroke, delineating aspects of arterial revascular

110 s deployed when the dispatchers suspected an acute stroke during emergency calls.

111 is one of the main causes of mortality after acute stroke, early dysphagia assessment may contribute

112 A total of 104 patients with acute stroke enrolled between 1991 and 1997 entered a do

113 CS use were available for 1971 patients with acute stroke enrolled into ENOS from February 2003 to Ap

114 euroimaging is an essential component of the acute stroke evaluation.

115 Hyperglycemia is common in patients with acute stroke, even in those without preexisting diabetes

116 icant effect on any outcome in patients with acute stroke except for an increase in major bleeding ev

117 Most patients with acute stroke exhibited some degree of preventability.

118 ovider capabilities and address shortages of acute stroke expertise nationwide.

119 robust evidence that screening patients with acute stroke for dysphagia reduces the risk of stroke-as

120 nosed SAP in 1088 patients who had dysphagic acute stroke from 37 UK stroke units between 21 April 20

121 ents was conducted within 3 months following acute stroke from July 9, 2003, to October 1, 2007.

122 acute ischemic stroke and differentiation of acute stroke from other processes that manifest with sud

123 effective in the initial differentiation of acute stroke from stroke mimics in the ER.

124 ardial infarction, congestive heart failure, acute stroke, gastrointestinal hemorrhage, hip fracture,

125 The slow progress in thrombolysis for acute stroke has been multifactorial.

126 lthough the inflammatory nature of M-MPhi in acute stroke has been well documented, their role during

127 cal treatment of the complications caused by acute stroke has contributed to decreased mortality, but

128 Reperfusion therapy for acute stroke has evolved from the initial use of intrave

129 from 1995 through 2012 were used to analyze acute stroke hospitalization rates among adults aged 18

130 Trends in acute stroke hospitalization rates by stroke type, age,

131 The aim of this study was to determine acute stroke hospitalization rates for children and youn

132 Acute stroke hospitalizations were identified by the pri

133 on are associated with worse outcomes during acute stroke; however, the optimal hemodynamic parameter

134 Amongst 40 patients with moderate to severe acute stroke imaged up to 26 h after onset, lactate conc

135 long-term mortality and cause of death after acute stroke in adults aged 18 through 50 years and to c

136 he safety and efficacy of thrombolysis after acute stroke in children have not been established.

137 ctive cohort study of patients admitted with acute stroke in England and Wales.

138 tinel could improve functional outcome after acute stroke in human beings.

139 n is still controversial in the treatment of acute stroke in hypertensive patients.

140 e stroke and promises to improve outcomes in acute stroke in the near future.

141 to optimise the treatment and prevention of acute stroke in these much older people will increasingl

142 arker models to assist with the diagnosis of acute stroke in those with mild symptoms.

143 The role of carotid artery stenting in acute stroke, including its use in the intracranial circ

144 M), reduced infarct size by 25% following an acute stroke induced by MCA occlusion for 90 min.

145 as it may yield new therapeutic targets for acute stroke injury and other neurological diseases invo

146 systems of care to provide timely access to acute stroke intervention to patients in the United Stat

147 Hyperglycaemia after acute stroke is a common finding that has been associate

148 Acute stroke is a medical emergency.

149 Acute stroke is a serious concern in emergency departmen

150 lateral circulation in patients suspected of acute stroke is afforded by a combination of PCT and CTA

151 using tissue plasminogen activator (tPA) in acute stroke is associated with increased risks of cereb

152 resonance imaging (MRI) for the diagnosis of acute stroke is increasing, this method has not proved m

153 Whether the outcome of acute stroke is influenced by Ag-specific activation of

154 trategy could dramatically transform the way acute stroke is managed in the United States.

155 Correct diagnosis of acute stroke is of paramount importance to clinicians to

156 The sole FDA approved treatment for acute stroke is tissue type plasminogen activator (tPA).

157 ypoxia is common in the first few days after acute stroke, is frequently intermittent, and is often u

158 MRI detected acute stroke (ischaemic or haemorrhagic), acute ischaemi

159 s (aged >16 years) admitted to hospital with acute stroke (ischaemic or primary intracerebral haemorr

160 cular CD4(+) T cells in the area surrounding acute stroke lesions, suggesting that IL-21-mediated bra

161 tients developed IPO concomitantly during an acute stroke-like episode.

162 c (CT) perfusion scans from 28 patients with acute stroke (<6 hours) due to major arterial occlusion,

163 could eventually play a significant role in acute stroke management, particularly in determining the

164 In acute stroke management, time is brain.

165 thrombolysis and mechanical thrombectomy in acute stroke management.

166 in neonatal brain than in adult brain after acute stroke may have major implications for the treatme

167 fits of blood pressure-lowering treatment in acute stroke might differ between patients with major is

168 to oxytocin before induction of experimental acute stroke model via oxygen-glucose deprivation-reperf

169 hms to predict ischemic tissue fate based on acute stroke MRI typically utilized data at a single tim

170 After acute stroke, multiparous mice had smaller infarcts, les

171 The most common misses were acute stroke (n = 3), aneurysm (n = 3), vascular occlusi

172 tion]) with cerebrovascular ischemic events (acute stroke, n = 20; subacute stroke, n = 2; chronic st

173 Acute stroke or hemorrhage, or delayed radiographic prog

174 on in a subgroup analysis of patients in the Acute Stroke or Transient Ischaemic Attack Treated with

175 d with a ST-elevation myocardial infarction, acute stroke, or trauma; had a cardiac arrest prior to a

176 me and should be considered the main goal in acute stroke patient management.

177 ine data from National Scottish datasets for acute stroke patients admitted between 2005 and 2011.

178 We enrolled 62 acute stroke patients admitted to our stroke unit during

179 atine tonsils and cervical lymph nodes of 28 acute stroke patients and 17 individuals free of neurolo

180 lial fibrillary astrocytic protein (GFAP) in acute stroke patients and healthy controls and investiga

181 Because an increasing number of acute stroke patients are treated with tPA, it is import

182 for deep vein thrombus (DVT) prophylaxis in acute stroke patients before and after publication of th

183 inally included with a total number of 3,936 acute stroke patients for analysis.

184 rticularly in determining the suitability of acute stroke patients for thrombolytic therapy.

185 Interhospital transfer of acute stroke patients is becoming increasingly important

186 tional outcome in the greatest proportion of acute stroke patients possible.

187 ed a multicenter cohort study of consecutive acute stroke patients scheduled to undergo endovascular

188 ntation performance, we found that of the 18 acute stroke patients tested, only the four patients wit

189 Acute stroke patients were categorized into "acute carot

190 Ninety acute stroke patients who previously received aspirin th

191 ion scans, predict 27-hour infarct volume in acute stroke patients who were treated with reperfusion

192 We recruited 413 acute stroke patients, 161 (39%) experienced SAI.

193 In 14 acute stroke patients, volumetric agreement between auto

194 In acute stroke patients, we measured FC in a dorsal attent

195 inical severity and stroke infarct volume in acute stroke patients.

196 evious model of 30 local hospitals receiving acute stroke patients.

197 y, and the treatment has been used safely in acute stroke patients.

198 of autologous MNCs were safe and feasible in acute stroke patients.

199 ffusion-weighted imaging (DWI) are common in acute stroke patients.

200 o improvements in the clinical management of acute stroke patients.

201 ised, controlled trial was undertaken in 457 acute-stroke patients (average age 76 years, 48% women)

202 ecludes many higher-risk (acute ischemic and acute stroke) patients from undergoing MRI and MRI-guide

203 proton transfer (APT) contrast for detecting acute stroke, pH effects were noninvasively imaged in is

204 re are no clinically validated biomarkers of acute stroke, previous studies have focused on markers a

205 Here we review recent imaging studies of the acute stroke process.

206 schemia was defined as posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) < 8.

207 In patients with acute stroke, rapid intervention is crucial to maximise

208 Children with acute stroke received alteplase infrequently and at time

209 We conclude that in patients with acute stroke receiving MT, success should be redefined a

210 In acute stroke, recognition and modification of risk facto

211 te ischemic stroke patients (1,645 patients; Acute STroke Registry and Analysis of Lausanne registry)

212 participating in the Paul Coverdell National Acute Stroke Registry.

213 not subjected to stroke indicated that these acute stroke-related changes in vascular function could

214 st that, at least in a subgroup of patients, acute stroke-related headache might be centrally driven.

215 ty of these procedures is usually defined by acute stroke risk, it is also becoming clear that far mo

216 pressure with lisinopril and labetalol after acute stroke seems to be a promising approach to reduce

217 necteplase in larger trials of patients with acute stroke seems warranted.

218 udy of all patients older than 18 years with acute stroke seen in the emergency department or admitte

219 mimics are an important subgroup admitted to acute stroke services and have a distinct demographic an

220 setting and the symptomatic effects of hyper-acute stroke shaped the form, content and manner of know

221 After acute stroke, short-interval intracortical inhibition (S

222 of vasopressor drugs to treat hypotension in acute stroke should be limited to selective situations.

223 Treatment of acute stroke should involve thrombolysis and attention t

224 gents that could be used in the treatment of acute stroke, should these proteins be made transportabl

225 hat, contrary to MMP inhibitor therapies for acute stroke, strategies that modulate MMPs may be neede

226 s were randomised less than 48 h after major acute stroke, stratified by severity of baseline neurolo

227 The European Cooperative Acute Stroke Study (ECASS) III demonstrated benefit to e

228 in the Enhanced Control of Hypertension and Acute Stroke Study (ENCHANTED) and the clinical predicto

229 (PH) was defined using European Cooperative Acute Stroke Study criteria.

230 ic in 9 (7%), and mild (European Cooperative Acute Stroke Study grades HI1 or HI2) in all but 1 child

231 95% CI = 0.82-1.70 per European Cooperative Acute Stroke Study II) after adjustment for age, stroke

232 s associated with sICH (European Cooperative Acute Stroke Study II) was evaluated, and we developed o

233 l Disorders and Stroke, European Cooperative Acute Stroke Study II, and Safe Implementation of Thromb

234 hemorrhage based on the European Cooperative Acute Stroke Study-II definition (any intracranial bleed

235 based, observational study that enrolled 100 acute stroke subjects.

236 bectomy (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, althoug

237 ients older than 18 years who presented with acute stroke symptoms at one of four remote spoke sites

238 for the initial evaluation of patients with acute stroke symptoms.

239 y elements of primary stroke centers include acute stroke teams, stroke units, written care protocols

240 7 major North American academic centers with acute stroke teams.

241 pril are effective antihypertensive drugs in acute stroke that do not increase serious adverse events

242 Overall, the study showed in patients with acute stroke the presence of myelin and neuronal Ags ass

243 rease the effective use of thrombolytics for acute stroke, the expertise of vascular neurologists mus

244 The treatment of acute stroke, the prevention and management of the many

245 Among nonhypoxic patients with acute stroke, the prophylactic use of low-dose oxygen su

246 hree areas provides optimism that additional acute stroke therapies can be developed to maximize bene

247 The development of additional acute stroke therapies to complement and supplement intr

248 Using acute stroke therapy as an illustration, we present an e

249 ures to limit risk, are urgent challenges in acute stroke therapy research.

250 many lessons that will help to guide future acute stroke therapy trials and enhance the likelihood o

251 e treated with intravenous or intra-arterial acute stroke therapy while these treatments were provide

252 lasminogen activator remains the mainstay of acute stroke therapy within the initial 4.5 hours after

253 to benefit far more stroke patients than any acute stroke therapy, and represents the greatest opport

254 the ischemic core present novel dimension to acute stroke therapy, focused on ischemia and not just t

255 as been learned about the presumed target of acute stroke therapy, the ischemic penumbra, and clinica

256 allowing more patients to be candidates for acute stroke therapy.

257 rcumvent the currently severe limitations of acute stroke therapy.

258 toward the development of MMP inhibitors for acute stroke therapy.

259 likely substantially influence the future of acute stroke therapy.

260 roke onset, which has initiated a new era of acute stroke therapy.

261 ves endeavor to raise public awareness about acute stroke to improve triage for emergency treatment,

262 roved functional outcome among patients with acute stroke treated with stent retrievers.

263 marize what is known about the use of MRI in acute stroke treatment (predominantly thrombolysis), to

264 METHODS AND The HASTE (Hurry Acute Stroke Treatment and Evaluation) project was imple

265 While most research thus far has focused on acute stroke treatment and neuroprotection, the exploita

266 Additional strategies to increase acute stroke treatment are needed.

267 Acute stroke treatment has entered a golden age, and man

268 Although the efficacy of acute stroke treatment is time dependent, the use of fix

269 African Americans receive acute stroke treatment less often than non-Hispanic whit

270 Among TOAST (Trial of Org 10172 in Acute Stroke Treatment) subtypes, adjusted for age, sex,

271 Data from the Trial of ORG10172 in Acute Stroke Treatment, a randomized trial of the hepari

272 he assessment of perfusion images as part of acute stroke treatment.

273 n, stroke risk factors, stroke severity, and acute stroke treatment.

274 and response of emergency medical services; acute stroke treatment; subacute stroke treatment and se

275 mic stroke (and TOAST [Trial of Org 10172 in Acute Stroke Treatment] subtypes) (effective sample size

276 Very few trials of acute stroke treatments show efficacy of a tested agent

277 e ischemic territory forms the basis of most acute stroke treatments.

278 uring the first 72 hours provided at 8 hyper-acute stroke units (HASUs) compared to the previous mode

279 Some patients admitted to acute stroke units are diagnosed as stroke mimics.

280 ional outcome and mortality in patients with acute stroke using a meta-analysis of the available evid

281 ypoattenuation, sensitivity for detection of acute stroke was 48% (nonenhanced scans) and 70% (angiog

282 hrough 50 years, 20-year mortality following acute stroke was relatively high compared with expected

283 e meaning of words, or lexical semantics) in acute stroke was strongly associated with the presence o

284 randomized clinical trial, 8003 adults with acute stroke were enrolled from 136 participating center

285 raphic protocol, 159 patients with suspected acute stroke were evaluated with both brain diffusion te

286 d in 691 consecutive patients with suspected acute stroke were examined.

287 comorbidities among those hospitalized with acute stroke were identified by secondary ICD-9-CM codes

288 clinical dysphagia admitted to hospital with acute stroke were randomly assigned to receive usual car

289 17 of whom had a final clinical diagnosis of acute stroke, were assessed.

290 e of these disorders occur immediately after acute stroke, whereas others can develop later, and yet

291 er-based interventional revascularization in acute stroke, which appears to be successful, has shifte

292 Among patients with acute stroke who had last been known to be well 6 to 24

293 tent of final infarct in seven patients with acute stroke who underwent follow-up CT or magnetic reso

294 anagement and complications of patients with acute stroke who were admitted to a stroke unit or to a

295 l characteristics of patients with suspected acute stroke who were admitted to hospital from the ER.

296 The delivery of care to patients with acute stroke will also need to incorporate newly proven

297 Improving outcomes for acute stroke will require patient education to encourage

298 We compared a group of 20 patients with acute stroke with anterior temporal pole damage to a gro

299 o organised stroke unit care for people with acute stroke, with active physiological monitoring and p

300 may be elevated in patients with sepsis and acute stroke without underlying acute coronary syndrome,